Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
Malchers F, Nogova L, van Attekum MH, Maas L, Brägelmann J, Bartenhagen C, Girard L, Bosco G, Dahmen I, Michels S, Weeden CE, Scheel AH, Meder L, Golfmann K, Schuldt P, Siemanowski J, Rehker J, Merkelbach-Bruse S, Menon R, Gautschi O, Heuckmann JM, Brambilla E, Asselin-Labat ML, Persigehl T, Minna JD, Walczak H, Ullrich RT, Fischer M, Reinhardt HC, Wolf J, Büttner R, Peifer M, George J, Thomas RK. Malchers F, et al. Among authors: gautschi o. J Clin Invest. 2023 Nov 1;133(21):e170217. doi: 10.1172/JCI170217. J Clin Invest. 2023. PMID: 37606995 Free PMC article.
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS. Gray JE, et al. Among authors: gautschi o. Clin Cancer Res. 2023 Sep 1;29(17):3340-3351. doi: 10.1158/1078-0432.CCR-22-3146. Clin Cancer Res. 2023. PMID: 37379430
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark MT, Rothschild SI, Addeo A, Janthur WD, Siano M, Boos L, Britschgi C, Früh M. Schuler A, et al. Among authors: gautschi o. Lung Cancer. 2024 Jan;187:107427. doi: 10.1016/j.lungcan.2023.107427. Epub 2023 Nov 22. Lung Cancer. 2024. PMID: 38043395
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort.
Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, Gautschi O, Aboubakar F, Muñoz-Couselo E, Pierret T, Rothschild SI, Cortiula F, Reynolds KL, Thibault C, Gavralidis A, Blais N, Barlesi F, Planchard D, Besse BMD. Remon J, et al. Among authors: gautschi o. ESMO Open. 2024 Apr 22;9(5):103004. doi: 10.1016/j.esmoop.2024.103004. Online ahead of print. ESMO Open. 2024. PMID: 38653155 Free PMC article.
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.
Barbier MC, Fengler A, Pardo E, Bhadhuri A, Meier N, Gautschi O. Barbier MC, et al. Among authors: gautschi o. Pharmacoeconomics. 2023 Dec;41(12):1641-1655. doi: 10.1007/s40273-023-01305-3. Epub 2023 Aug 12. Pharmacoeconomics. 2023. PMID: 37572261 Free PMC article.
IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer.
Asamura H, Nishimura KK, Giroux DJ, Chansky K, Hoering A, Rusch V, Rami-Porta R; Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, and Participating Institutions. Asamura H, et al. J Thorac Oncol. 2023 May;18(5):564-575. doi: 10.1016/j.jtho.2023.01.088. Epub 2023 Feb 10. J Thorac Oncol. 2023. PMID: 36773775 Free article.
303 results